Gene: TFAP2B

7021
AP-2B|AP2-B|PDA2
transcription factor AP-2 beta
protein-coding
6p12.3
Ensembl:ENSG00000008196 MIM:601601 Vega:OTTHUMG00000014836 UniprotKB:Q92481
NG_008438.1
PubMed
0   ANCO-SNPs
ND|AD
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.171e-1 (AD)  7.625e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FOXD20.795
TRABD2B0.764
OR51E10.743
CDC20B0.742
ALX40.738
MYOCD0.738
BMX0.732
NR2F2-AS10.732
FOXC20.727
PTGDR0.72

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MARCH11-0.288
ASPDH-0.285
RND1-0.282
BAIAP2L2-0.28
C16orf46-0.279
MYADML2-0.279
FN3K-0.274
RDH12-0.273
OGDHL-0.271
FCHO1-0.271

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of TFAP2B mRNA26690555
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of TFAP2B gene27153756
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in decreased expression of TFAP2B mRNA28522335
D001280AtrazineAtrazine results in decreased expression of TFAP2B mRNA25929836
D001280AtrazineAtrazine results in decreased expression of TFAP2B mRNA22378314
C487081belinostatbelinostat results in increased expression of TFAP2B mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of TFAP2B mRNA22316170
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of TFAP2B mRNA22228805
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of TFAP2B mRNA22228805
C006780bisphenol Abisphenol A affects the expression of TFAP2B mRNA25181051
D002104CadmiumCadmium results in decreased expression of TFAP2B mRNA21120746
C010063carbonyl sulfidecarbonyl sulfide affects the expression of TFAP2B mRNA19395590
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in increased expression of TFAP2B mRNA26272509
D0198131,2-Dimethylhydrazine"[APC protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in decreased expression of TFAP2B mRNA"27840820
D018690Excitatory Amino Acid AgonistsExcitatory Amino Acid Agonists results in increased expression of and results in increased activity of TFAP2B protein17550430
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of TFAP2B mRNA21179406
C561695(+)-JQ1 compound(+)-JQ1 compound affects the expression of TFAP2B mRNA26733615
C561695(+)-JQ1 compound(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TFAP2B mRNA]26733615
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of TFAP2B mRNA23430699
C561695(+)-JQ1 compoundpanobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TFAP2B mRNA]26733615
D007854LeadLead affects the expression of TFAP2B mRNA28903495
D008345ManganeseManganese results in increased expression of TFAP2B mRNA17175027
C025340manganese chloridemanganese chloride results in increased expression of TFAP2B mRNA17175027
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of TFAP2B mRNA28001369
D009532NickelNickel affects the expression of TFAP2B mRNA14575637
D009532NickelNickel results in decreased expression of TFAP2B mRNA24768652|2558310
D009532Nickeltrichostatin A inhibits the reaction [Nickel affects the expression of TFAP2B mRNA]14575637
C496932panobinostat(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TFAP2B mRNA]26733615
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C496932panobinostatpanobinostat affects the expression of TFAP2B mRNA26733615
C496932panobinostatpanobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TFAP2B mRNA]26733615
C496932panobinostatpanobinostat results in increased expression of TFAP2B mRNA26272509
C086401pentabromodiphenyl etherpentabromodiphenyl ether results in decreased expression of TFAP2B mRNA26705709
C025462sulindac sulfidesulindac sulfide results in increased expression of TFAP2B mRNA16184548
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of TFAP2B mRNA24058054
D019284ThapsigarginThapsigargin results in decreased expression of TFAP2B mRNA22378314
D014212TretinoinTretinoin results in decreased expression of TFAP2B mRNA23724009
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C012589trichostatin Atrichostatin A inhibits the reaction [Nickel affects the expression of TFAP2B mRNA]14575637
C012589trichostatin Atrichostatin A results in increased expression of TFAP2B mRNA24935251|2627250
C012589trichostatin Atrichostatin A results in decreased expression of TFAP2B mRNA15901671
D014415TunicamycinTunicamycin results in decreased expression of TFAP2B mRNA22378314
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of TFAP2B mRNA23179753|2800136
D014635Valproic AcidValproic Acid results in decreased methylation of TFAP2B gene29154799
D014635Valproic AcidValproic Acid results in increased expression of TFAP2B mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in decreased expression of TFAP2B mRNA15901671
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of TFAP2B gene25560391
C029297vinylidene chloridevinylidene chloride results in decreased expression of TFAP2B mRNA26682919
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA"27188386
C111237vorinostatvorinostat results in increased expression of TFAP2B mRNA26272509
C088658zoledronic acidzoledronic acid results in decreased expression of TFAP2B mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IBA21873635  
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IDA7555706  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-IBA21873635  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-IDA7555706  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0000983transcription factor activity, RNA polymerase II core promoter sequence-specific DNA binding-ISS-  
GO:0001077transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IEA-  
GO:0001158enhancer sequence-specific DNA binding-IDA16373396  
GO:0003677DNA binding-TAS12072434  
GO:0003682chromatin binding-IEA-  
GO:0003700DNA-binding transcription factor activity-IDA11505339  12169688  16373396  
GO:0003713transcription coactivator activity-IDA7555706  
GO:0003713transcription coactivator activity-ISS-  
GO:0003714transcription corepressor activity-IDA7559606  
GO:0003714transcription corepressor activity-ISS-  
GO:0005515protein binding-IPI7555706  11694877  12072434  12586840  19115315  
GO:0042803protein homodimerization activity-IPI11505339  
GO:0043027cysteine-type endopeptidase inhibitor activity involved in apoptotic process-ISS-  
GO:0043565sequence-specific DNA binding-IDA11505339  12169688  
GO:0046982protein heterodimerization activity-IPI11505339  
GO:0046983protein dimerization activity-IDA12072434  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IDA7559606  
GO:0000122negative regulation of transcription by RNA polymerase II-TAS-  
GO:0001822kidney development-ISS-  
GO:0003091renal water homeostasis-ISS-  
GO:0006006glucose metabolic process-IMP15940393  16373396  19325541  
GO:0006355regulation of transcription, DNA-templated-IDA12169688  
GO:0006357regulation of transcription by RNA polymerase II-IBA21873635  
GO:0006366transcription by RNA polymerase II-IEA-  
GO:0006915apoptotic process-IEA-  
GO:0008284positive regulation of cell proliferation-IDA17525748  
GO:0008285negative regulation of cell proliferation-IDA20607706  
GO:0010226response to lithium ion-IEA-  
GO:0010842retina layer formation-IEP20607706  
GO:0010960magnesium ion homeostasis-ISS-  
GO:0030510regulation of BMP signaling pathway-ISS-  
GO:0035136forelimb morphogenesis-ISS-  
GO:0035137hindlimb morphogenesis-ISS-  
GO:0035810positive regulation of urine volume-ISS-  
GO:0035909aorta morphogenesis-ISS-  
GO:0042127regulation of cell proliferation-IBA21873635  
GO:0042493response to drug-IEA-  
GO:0042593glucose homeostasis-ISS-  
GO:0043066negative regulation of apoptotic process-IDA17525748  
GO:0043066negative regulation of apoptotic process-ISS-  
GO:0043154negative regulation of cysteine-type endopeptidase activity involved in apoptotic process-ISS-  
GO:0043524negative regulation of neuron apoptotic process-IEA-  
GO:0043525positive regulation of neuron apoptotic process-IDA20607706  
GO:0043588skin development-IEA-  
GO:0045444fat cell differentiation-IEP16373396  
GO:0045595regulation of cell differentiation-IDA20607706  
GO:0045892negative regulation of transcription, DNA-templated-IDA20607706  
GO:0045893positive regulation of transcription, DNA-templated-IDA11505339  
GO:0045893positive regulation of transcription, DNA-templated-IMP16373396  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA7555706  12169688  
GO:0045944positive regulation of transcription by RNA polymerase II-TAS-  
GO:0048485sympathetic nervous system development-ISS-  
GO:0048856anatomical structure development-IBA21873635  
GO:0050796regulation of insulin secretion-IMP15940393  19325541  
GO:0055062phosphate ion homeostasis-ISS-  
GO:0055074calcium ion homeostasis-ISS-  
GO:0055075potassium ion homeostasis-ISS-  
GO:0055078sodium ion homeostasis-ISS-  
GO:0072017distal tubule development-ISS-  
GO:0072044collecting duct development-ISS-  
GO:0072210metanephric nephron development-IEA-  
GO:0097070ductus arteriosus closure-ISS-  
GO:0097275cellular ammonia homeostasis-ISS-  
GO:0097276cellular creatinine homeostasis-ISS-  
GO:0097277cellular urea homeostasis-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IC12169688  
GO:0005634nucleus-IDA20607706  
GO:0005654nucleoplasm-TAS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-212436Generic Transcription PathwayTAS
R-HSA-212436Generic Transcription PathwayIEA
R-HSA-2990846SUMOylationIEA
R-HSA-3108232SUMO E3 ligases SUMOylate target proteinsIEA
R-HSA-3232118SUMOylation of transcription factorsIEA
R-HSA-392499Metabolism of proteinsIEA
R-HSA-597592Post-translational protein modificationIEA
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-73857RNA Polymerase II TranscriptionIEA
R-HSA-74160Gene expression (Transcription)TAS
R-HSA-74160Gene expression (Transcription)IEA
R-HSA-8864260Transcriptional regulation by the AP-2 (TFAP2) family of transcription factorsTAS
R-HSA-8864260Transcriptional regulation by the AP-2 (TFAP2) family of transcription factorsIEA
R-HSA-8866904Negative regulation of activity of TFAP2 (AP-2) family transcription factorsTAS
R-HSA-8866904Negative regulation of activity of TFAP2 (AP-2) family transcription factorsIEA
R-HSA-8866907Activation of the TFAP2 (AP-2) family of transcription factorsTAS
R-HSA-8866910TFAP2 (AP-2) family regulates transcription of growth factors and their receptorsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23978819Generalization of adiposity genetic loci to US Hispanic women. (2013 Aug 26)Graff MNutr Diabetes
19778525Transcription factor AP2 beta involved in severe female alcoholism. (2009 Dec 11)Nordquist NBrain Res